SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

MLA

Azzabi A., et al. SCOT: A Comparison of Cost-Effectiveness from a Large Randomised Phase III Trial of Two Durations of Adjuvant Oxaliplatin Combination Chemotherapy for Colorectal Cancer. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305136923&authtype=sso&custid=ns315887.

APA

Azzabi A., Webb A., Cunningham D., Hickish T., Weaver A., Gollins S., Wasan H.S., Paul J., Robles-Zurita J., Boyd K.A., Briggs A.H., Iveson T., Kerr R.S., Saunders M.P., Cassidy J., Hollander N.H., Tabernero J., Segelov E., Glimelius B., … Farrugia D. (2018). SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

Chicago

Azzabi A., Webb A., Cunningham D., Hickish T., Weaver A., Gollins S., Wasan H.S., et al. 2018. “SCOT: A Comparison of Cost-Effectiveness from a Large Randomised Phase III Trial of Two Durations of Adjuvant Oxaliplatin Combination Chemotherapy for Colorectal Cancer.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305136923&authtype=sso&custid=ns315887.